Identification of Hsp90 inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer
E. M. Mrozek, V. Bajaj, Y. Guo, I. Malinowska, J. Zhang, D. J. Kwiatkowski
This study identifies HSP90 inhibitors as potential drugs for TSC1/TSC2 deficient cancer but finds rapamycin is more effective in vivo despite modest in vitro inhibition.
bioRxiv · Feb 26, 2021Cancer Biology